文献速递血栓与止血

SynthoPlate™(合成血小板)技术的体外表征及在严重血小板减少小鼠中的体内评价

In vitro characterization of SynthoPlate™ (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice.
PubMed 文献 · J Thromb Haemost · 2017-01-01

本研究通过体外聚集、荧光显微镜、微流控及凝血酶与纤维蛋白生成实验,以及严重血小板减少小鼠的体内实验,评价SynthoPlate™(合成血小板)对血小板和血浆的影响、全身安全性及止血效果。结果显示SynthoPlate™不激活静息血小板或系统性促进凝血,但可放大出血部位活化血小板的招募与聚集、位点选择性增强纤维蛋白生成,剂量依赖性缩短血小板减少小鼠出血时间至正常水平,循环停留时间合理且主要经肝脾清除。

要点

  • SynthoPlate™不聚集静息血小板,也不在血浆中自发促进凝血。
  • SynthoPlate™可放大出血部位活化血小板的招募与聚集,位点选择性增强纤维蛋白生成。
  • 在严重血小板减少小鼠中,SynthoPlate™剂量依赖性缩短出血时间至正常小鼠水平。

核心结论

  • 结果表明SynthoPlate™作为合成血小板替代物在血小板相关出血并发症的输血治疗中具有前景。

研究设计与样本

  • 体外采用聚集实验、荧光显微镜、微流控及凝血酶与纤维蛋白生成实验评价SynthoPlate™对血小板和血浆的影响。
  • 体内在严重血小板减少(TCP)小鼠中,通过血浆凝血酶原与纤维蛋白实验评价全身安全性,并通过尾横断出血时间评价止血效果。

主要发现

  • SynthoPlate™不聚集静息血小板,也不在血浆中自发促进凝血,但能放大出血部位活化血小板的招募和聚集,从而位点选择性增强纤维蛋白生成。
  • SynthoPlate™剂量依赖性缩短TCP小鼠出血时间,至与正常小鼠相当的水平。
  • SynthoPlate™具有合理的循环停留时间,主要经肝脏和脾脏清除。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Platelet transfusion suffers from availability, portability, contamination, and short shelf-life. SynthoPlate™ (synthetic platelet technology) can resolve platelet transfusion limitations. SynthoPlate™ does not activate resting platelets or stimulate coagulation systemically. SynthoPlate™ significantly improves hemostasis in thrombocytopenic mice dose-dependently. SUMMARY: Background Platelet transfusion applications face severe challenges, owing to the limited availability and portability, high risk of contamination and short shelf-life of platelets. Therefore, there is significant interest in synthetic platelet substitutes that can provide hemostasis while avoiding these issues. Platelets promote hemostasis by injury site-selective adhesion and aggregation, and propagation of coagulation reactions on their membranes. On the basis of these mechanisms, we have developed a synthetic platelet technology (SynthoPlate™) that integrates platelet-mimetic site-selective 'adhesion' and 'aggregation' functionalities via heteromultivalent surface decoration of lipid vesicles with von Willebrand factor-binding, collagen-binding and active platelet integrin glycoprotein (GP) IIb-IIIa-binding peptides. Objective To evaluate SynthoPlate for its effects on platelets and plasma in vitro, and for systemic safety and hemostatic efficacy in severely thrombocytopenic mice in vivo. Methods In vitro, SynthoPlate was evaluated with aggregometry, fluorescence microscopy, microfluidics, and thrombin and fibrin generation assays. In vivo, SynthoPlate was evaluated for systemic safety with prothrombin and fibrin assays on plasma, and for hemostatic effects on tail-transection bleeding time in severely thrombocytopenic (TCP) mice. Results SynthoPlate did not aggregate resting platelets or spontaneously promote coagulation in plasma, but could amplify the recruitment and aggregation of active platelets at the bleeding site, and thereby site-selectively enhance fibrin generation. SynthoPlate dose-dependently reduced bleeding time in TCP mice, to levels comparable to those in normal mice. SynthoPlate has a reasonable circulation residence time, and is cleared mostly by the liver and spleen. Conclusion The results demonstrate the promise of SynthoPlate as a synthetic platelet substitute in transfusion treatment of platelet-related bleeding complications.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Shukla M, Sekhon UD, Betapudi V, et al. In vitro characterization of SynthoPlate™ (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice. J Thromb Haemost. 2017. PMID: 27925685. doi:10.1111/jth.13579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。